Trial Profile

LIMIT Melanoma: (Lysosomal Inhibition + Melanoma ImmunoTherapy) A Phase 1/2 Open Label Trial of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Patients With Advanced Melanoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hydroxychloroquine (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Malignant melanoma
Focus Adverse reactions; Therapeutic Use
Acronyms LIMIT; LIMIT Melanoma

05 Oct 2023 Planned End Date changed from 30 Oct 2023 to 30 Oct 2025.
05 Oct 2023 Planned primary completion date changed from 30 Oct 2023 to 30 Oct 2025.
21 Oct 2020 Planned primary completion date changed from 30 Jul 2023 to 30 Oct 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com